European Pharmaceutical Review

MAY 19, 2023

Final draft guidance has been published for the first National Institute for Health and Care Excellence (NICE)-recommended treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction. The study enrolled 6,263 randomised patients. This was reported as 16.4 percent in the dapagliflozin group and 19.5

Hospitals 103

Hospitals 103

LifeProNow

MARCH 17, 2023

March 15, 2023: ” Bristol Myers Squibb announced meaningful progress toward its global inclusion & diversity goals and health equity commitments, meeting and exceeding some goals ahead of schedule. BMS and the Foundation are on track to achieve many of their respective goals and have exceeded some ahead of schedule.

100

100

LifeProNow

FEBRUARY 1, 2024

Our collaboration with the FUJIFILM Cellular Dynamics and Opsis Therapeutics team has allowed us to execute important IND-enabling activities, and we are excited to advance OpCT-001 toward the clinic, with an IND filing planned for this year.”

130

130

pharmaphorum

SEPTEMBER 30, 2022

Houda Hachad is vice president of clinical operations at AccessDx Laboratory, where she focuses on expanding the use of pharmacogenomic testing, a major piece of the puzzle for precision medicine. And that same technology and approach can also be of benefit to other chronic conditions, from cardiovascular disease to behavioural health.

98

98

European Pharmaceutical Review

NOVEMBER 7, 2022

Results from the EMPA-KIDNEY Phase III clinical trial announced at the American Society of Nephrology (ASN)’s Kidney Week 2022, demonstrated Jardiance ® (empagliflozin) reduced the risk of kidney disease progression or cardiovascular death by 28 percent versus placebo in adults with chronic kidney disease (CKD). to 0.95, p=0.0025.

Diabetes 83

Diabetes 83

Express Pharma

FEBRUARY 16, 2024

Gagandeep Singh Bedi, Managing Director, Boehringer Ingelheim India said, “Chronic kidney disease is an important health issue, and there is a significant unmet need for therapies that slow disease progression and improve outcomes.

Diabetes 59

Diabetes Hospitals 59

Pharmaceutical Technology

APRIL 19, 2023

Bayer has announced that it will shift the focus of its drug research away from women’s health to four core therapeutic areas: oncology, cardiovascular, neurology and rare diseases/immunology.

52

52

Board Vitals - Pharmacist

NOVEMBER 28, 2022

Most students take the USMLE® Step 2 CK after completing their third year of medical school, immediately after clinical rotations. Maintenance/Disease Prevention: 8-12% Pharmacotherapy: 8-12% Clinical Interventions: 6-10% Mixed Management: 12-16% . The following topics are on the USMLE Step 1 : . USMLE Step 2 CK.

Medical Schools 98

Medical Schools Communication Immunity Immunization 98

pharmaphorum

DECEMBER 17, 2021

There is no doubt that the COVID-19 pandemic has accelerated the adopt of digital health. Read on for a look at some of the biggest stories from Frontiers Health, how digital is making healthcare more patient-friendly and key ways to optimise decentralised clinical trials. Digital health: making medicine more human.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

European Pharmaceutical Review

AUGUST 28, 2023

In the Phase III extension trial ORION-8 , inclisiran in addition to statin therapy provided consistent LDL-C reduction beyond six years in patients with atherosclerotic cardiovascular disease (ASCVD), increased risk of ASCVD or heterozygous familial hypercholesterolemia (HeFH).

98

98

Pharmaceutical Technology

OCTOBER 27, 2022

Bayer has received approval from Health Canada for finerenone as an adjunct to standard-of-care treatment for chronic kidney disease (CKD) and type 2 diabetes (T2D) in adult patients. Health Canada approval is based on the positive data from the Phase III FIDELIO-DKD and FIGARO-DKD clinical trials of Kerendia.

Diabetes 52

Diabetes Hospitals 52

Pharmaceutical Business Review

JULY 11, 2023

The label update reinforces the safety and effectiveness data of Leqvio generated by the VictORION clinical trial programme, claimed the company. Leqvio was initially approved by the FDA in December 2021. It is claimed to be the first and only small interfering RNA (siRNA) therapy to reduce LDL-C.

Labelling 75

Labelling 75

pharmaphorum

FEBRUARY 25, 2022

The approval builds upon previously secured indications, including the use of Jardiance to reduce the risk of cardiovascular death plus hospitalisation for heart failure with reduced left ventricular ejection fraction (LVEF), which the FDA greenlighted in 2021. absolute risk reduction, 0.79

Diabetes 100

Diabetes 100

Pharmaceutical Business Review

FEBRUARY 21, 2024

The seed financing will be instrumental in advancing the pre-clinical development of IsomAb’s lead antibody, ISM-001. We are delighted to have attracted a group of high-quality investors to support the early development of our novel programme toward CTA filing to enter the clinic.”

Diabetes 59

Diabetes 59

European Pharmaceutical Review

JANUARY 19, 2023

Winn Diversity in Clinical Trials Award Program ( Winn Award Program ), established by the Bristol Myers Squibb Foundation (BMSF). The additional support from Amgen is set to reach more than 300 diverse and community-oriented clinical investigators by 2027.

85

85

pharmaphorum

OCTOBER 27, 2020

Analysing real-world health data could help overcome the bias towards men in traditional medical research, says Sensyne Health’s Dr Lucy Mackillop. Therefore, it is important to increase the collection and analysis of women’s health data so better insights can be gained for supporting their care.

Diabetes 113

Diabetes Medical Records Hospitals 113

pharmaphorum

AUGUST 6, 2021

There was a dramatic increase in the launch of health-related mobile applications last year, taking the total number on offer in app stories to 350,000 – and while average quality is currently “middling” it is on the rise, according to a report from IQVIA.

Diabetes 145

Diabetes 145

Express Pharma

APRIL 27, 2023

German drugmaker Bayer recently announced that it will shift the focus of its drug research away from women’s health to four core therapeutic areas: oncology, cardiovascular, neurology, and rare diseases/immunology. billion in 2022, respectively.” billion in 2022, respectively.”

53

53

PharmaShots

FEBRUARY 6, 2023

The device is used for remote patient monitoring, home health, and clinical trials She also elaborated about the data used for the pre-marketing submission with FDA. Hofhine: The Pulse is a world’s first connected vascular biometric monitor for at-home and in-clinic monitoring.

Health and Personal Care Stores 53

Health and Personal Care Stores Biosimilars HIPAA Pharmaceutical Companies 53

pharmaphorum

JANUARY 17, 2023

Late last year, pharmaphorum spoke with AstraZeneca’s Ben Challis, VP and head of translational science and experimental medicine, cardiovascular, renal, and metabolism (CVRM), together with Magnus Jörnten-Karlsson, executive director of Unify. Unify, launched in December 2020, is AstraZeneca’s patient app and clinical trial support tool.

Drug Development 98

Drug Development 98

Pharmaceutical Technology

JUNE 16, 2023

The Abu Dhabi Department of Health (DoH) in the UAE has made a declaration of collaboration with Mass General Brigham’s (MGB) International Center for Genetic Disease (iCGD) to advance life sciences.

52

52

European Pharmaceutical Review

OCTOBER 30, 2023

A large-scale study led by researchers at the University of Cincinnati and New York’s largest health care provider, Northwell Health, suggests that metformin can help prevent or reduce weight gain in youth taking second-generation antipsychotics (SGAs) to treat bipolar disorder.

Diabetes 102

Diabetes 102

pharmaphorum

JANUARY 25, 2022

What does the current picture of cardiovascular disease in Europe look like? Surprisingly for many, cardiovascular disease (CVD) is Europe’s leading cause of death – not cancer, as many people would assume. The causes and risk factors for CVD are many and highly varied, as reflected in clinical guidelines.

Diabetes 57

Diabetes 57

pharmaphorum

OCTOBER 5, 2020

billion takeover that marks a step up in its development of cardiovascular drugs. The all-cash deal is mainly about MyoKardia’s mavacamten drug that BMS thinks could be a first-in-class treatment for hypertrophic cardiomyopathy (HCM) – a form of heart disease – based on clinical data reported in the spring.

57

57

pharmaphorum

SEPTEMBER 1, 2021

An artificial intelligence algorithm already shown to be able to detect atrial fibrillation (AF) in clinical testing has also shown its worth in a real-world setting, according to its developers. The control group had access to usual clinical practice for diagnosis of AF. ” AF affects an estimated 1.5

127

127

pharmaphorum

JUNE 25, 2021

Amarin’s Craig Granowitz discusses the impact of COVID on cardiovascular disease treatment and explains why there’s still a long way to go till we can truly tackle these diseases. In the US there were about 550,000 deaths in the first year of COVID – but every year in the US there are around 800,000 deaths due to cardiovascular disease.

Communication 98

Communication Drug Development 98

pharmaphorum

SEPTEMBER 6, 2021

UK researchers have used artificial intelligence (AI) to develop a way to identify patients with heart failure who would benefit from treatment with beta blockers, by interrogating data from nine landmark clinical trials. The researchers wanted to see if their AI could select the patients who would benefit the most from treatment with them.

145

145

Putting Patients First Blog

FEBRUARY 29, 2024

In its 32-year history, the CDMRP has funded research into a plethora health care issues that impact the chronic illness community including breast cancer, chronic pain management, epilepsy, melanoma, multiple sclerosis, etc. In FY2023, over 30 health conditions were examined within CDMRP. CDMRP funding is more targeted in its funding.

52

52

Putting Patients First Blog

APRIL 13, 2023

This year’s Symposium theme is Patient Empowerment in the Digital Health Era , and will focus on digital technologies, the science of patient engagement, and health equity. Dr. Califf has had a long and distinguished career as a physician, researcher, and leader in the fields of science and medicine.

52

52

Express Pharma

SEPTEMBER 20, 2023

With the recent clinical data that has come out of both the SURMOUNT and SURPASS trials for both T2D and obesity, it is likely that Mounjaro will become the leading GLP-1 therapy in the National Health Service (NHS) in the UK, says GlobalData.

Diabetes 102

Diabetes 102

European Pharmaceutical Review

OCTOBER 18, 2022

Over the next five years research at the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (BRC) will include vaccine development for infectious diseases, funded in part by a £12 million grant from the National Institute for Health Research (NIHR).

Vaccines 80

Vaccines Hospitals 80

Board Vitals - Pharmacist

JANUARY 22, 2024

2024 ANCC AGACNP Outline : Core Competencies 23% Clinical Practice 45% Professional Role: 32% 2024 AACN ACNPC-AG Outline : 80% of the items test Clinical Judgment related to nursing care of the adult-gerontology patient population (young adults, older adults and frail elderly). How can I study?

100

100

pharmaphorum

MARCH 21, 2022

A clinical trial has shown that patients with cardiovascular disease who need cardiac rehabilitation were more likely to take part in a digital programme than face-to-face sessions. ” Figures from Australia suggest that boosting cardiac rehabilitation participation from 30% to 50% to 5% would result in net savings of A$46.7

52

52

PharmaShots

MAY 19, 2023

battery for long-term monitoring such as those undergoing therapy & are at risk of developing further arrhythmias i.e., AF The system uses Bluetooth technology to remain connected to a transmitter that checks heart rhythms every 20 seconds & transmits results in real-time to the clinic’s portal.

40

40

pharmaphorum

NOVEMBER 15, 2021

Johnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms in a clinical trial that relied entirely on remote monitoring of symptoms using a smartphone app. billion in 2016 before the product was linked to an increased risk of lower limb amputation.

Diabetes 104

Diabetes Labelling 104

Pharmaceutical Technology

JULY 20, 2022

Prescribing it] requires knowledge of a patient’s medical history, as well as clinical monitoring for side effects and follow-up care to determine whether a patient is improving—requirements far beyond a pharmacist’s scope and training,” as per a statement by AMA president Jack Resneck.

Labelling 111

Labelling Community Pharmacies Medical Records Communication 111

Express Pharma

AUGUST 11, 2023

Pioneering science is accelerating our understanding of disease, helping us better predict clinical success, develop and deliver life changing medicines and increase engagement in the clinic and beyond. COVID-19 has exposed the vulnerabilities of health systems across the world.

Communication 95

Communication Diabetes 95